United States: CMS's Self-Referral Disclosure Protocol: New Avenue for Stark Disclosures or One-Way Street?

As reported in our previous Legal News Alerts ( http://www.foley.com/publications/pub_detail.aspx?pubid=7464 and http://www.foley.com/publications/pub_detail.aspx?pubid=6995), the Patient Protection and Affordable Care Act of 2010 (PPACA) required the Department of Health and Human Services (DHHS) to have established, by no later than September 23, 2010, a self-referral disclosure protocol, under which health care providers may voluntarily report actual or potential Stark violations to CMS. This long-awaited date has arrived, and CMS has just issued its Voluntary Self-Referral Disclosure Protocol (SRDP) guidance. While the guidance provides welcome relief in at least one respect by providing for suspension of the 60-day deadline for reporting and refunding overpayments, providers may be surprised and disappointed in the SRDP's failure to provide any assurances of reduced penalties, particularly since the SRDP fails to provide any avenue for resolution of purely "technical" Stark violations.

Suspension of Refund Deadline

Section 6402 of PPACA established a deadline for reporting and returning overpayments by 60 days after the date the overpayment was "identified" (or, if later, the date any corresponding cost report is due). Notably, CMS states in the SRDP that this 60-day deadline will be suspended at the time the provider electronically submits an SRDP disclosure (and receives e-mail confirmation from CMS that the disclosure has been received), until a settlement agreement is entered (or until the provider withdraws from, or CMS removes the provider from, the SRDP process).

This allays the concern that providers might have been required to make a full refund of all "Stark-tainted" reimbursement prior to engaging in what could be potentially protracted settlement negotiations with CMS following a disclosure. Possibly, this suspension of the refund deadline also applies to patient refunds of copayments arising out of Stark-tainted services, but this is far from clear. CMS reminds providers of the statutory requirement to make refunds to individuals, but does not address the specific timing that is required for these refunds.

Nature of Disclosures CMS Will Accept Under the SRDP

Significant question has surrounded the issue of how the SRDP would interrelate with the self-disclosure protocol (SDP) that the Office of Inspector General (OIG) has had in place since 1998. CMS's guidance states that Stark issues that "may also raise liability risks" under the federal Anti-Kickback Statute (AKS) should be disclosed through the OIG's SDP, and that parties should not disclose the same conduct to both CMS and OIG. Accordingly, providers will need to make assessments of the potential that the conduct in question could be viewed as an AKS violation (and therefore properly disclosed to OIG rather than CMS).

Additionally, in the event the provider takes the position that the conduct in question does not implicate the AKS, it still runs the risk that CMS will take a contrary position. CMS's guidance states that CMS may use a party's disclosure to recommend to OIG and the U.S. Department of Justice that they intervene to resolve possible liability under the AKS, the False Claims Act, or other law. CMS's guidance adds the somewhat ominous statement that "the disclosing party's initial decision of where to refer a [Stark] matter should be made carefully."

CMS's guidance also indicates that a party that is already subject to government inquiry (including investigations, audits, or routine oversight activities) will not automatically be precluded from the SRDP, so long as the disclosure is made in good faith and not in an attempt to circumvent an ongoing inquiry.

Content of the Disclosure Submission

Disclosures must be submitted electronically to 1877SRDP@cms.hhs.gov, followed by a mailed copy. After reviewing the submission, CMS will send a letter either accepting or rejecting the disclosure. The required content of the disclosure submission is very similar to what is currently required under the OIG's SDP. Among other items, the submission should include:

  • Detailed identifying information regarding the disclosing party, as well as the names of other entities and individuals believed to be implicated
  • A description of the matter being disclosed
  • A statement outlining why the party believes a Stark violation may have occurred, including a complete legal analysis of the application of the Stark law
  • The circumstances under which the matter was discovered and the measures taken to address the issue and prevent future abuses
  • Whether the party has knowledge that the matter is under current inquiry by a government agency or contractor
  • A financial analysis, itemized by year, of the potential Stark penalty (i.e., the amount of tainted reimbursement received)

CMS's Actions Following an SRDP Submission

Following submission, CMS will review the relevant circumstances to determine an appropriate resolution. This will including verifying the information in the provider's disclosure. As part of this process, CMS will require access to "all financial statements, notes, disclosures, and other supporting documents without the assertion of privileges or limitations." Although "in the normal course of verification, CMS will not request communications subject to the attorney-client privilege," CMS may insist on review of materials that may be covered by the work-product doctrine.

Providers should be aware that any additional issues outside of the scope of the disclosure that CMS discovers during its verification process may be treated as new matters outside the SRDP (and therefore subject to separate investigation and potential sanctions).

CMS's Penalty Determination

PPACA expressly authorizes CMS to reduce the amount of the Stark penalty (i.e., refund of all tainted reimbursement received) as part of the SRDP. PPACA lists three specific factors that CMS may consider in reducing the amounts otherwise owed: (1) the nature and extent of the improper or illegal practice; (2) the timeliness of the self-disclosure; and (3) the cooperation in providing additional information related to the disclosure. In its guidance, CMS lists two additional factors that it will consider: the "litigation risk associated with the matter disclosed," and the disclosing party's financial position. CMS does not explain what it means by litigation risk. Presumably, this consideration would include the risk that the government would not prevail in a potential Stark action brought against the provider, should the provider decline to settle.

Although CMS states that it may consider the foregoing factors, it also states "that it has no obligation to reduce any amounts due and owing." Rather, CMS indicates that it will "make an individual determination as to whether a reduction is appropriate based on the facts and circumstances of each disclosed actual or potential violation." CMS explains that, given the variability of the nature and circumstances of different violations, it will need to evaluate each matter to determine an appropriate resolution.

Implications for Providers

The most notable and, frankly, troubling aspect of the guidance is CMS's firm statement that it has no obligation to reduce the penalty that it will impose below the Stark damages amount (i.e., refund of all tainted reimbursement). Nor does CMS give any indication of the amount of reduction it might be inclined to offer in appropriate cases. This is in striking contrast to OIG's SDP, under which OIG announced (in its "Open Letter" dated April 24, 2006) that, "subject to the facts and circumstances of the case, OIG will generally settle SDP matters for an amount near the lower end of [the damages] continuum, i.e., a multiplier of the value of the financial benefit conferred by the hospital upon the physician(s)." In fact, in its follow-up Open Letter dated April 15, 2008, OIG stated that it "committed to settling liability ... generally for a multiplier of the value of the financial benefit conferred." [emphasis added].

The OIG's approach (a multiplier of the financial benefit) has often resulted in a settlement amount that is substantially lower than the amount of Stark damages. This has been especially true in cases of purely technical Stark violations, such as failure to properly document an arrangement in writing, failure to procure all necessarily signatures, or expiration of a services agreement or lease beyond the regulatory "holdover" period (but where the arrangement otherwise was legally compliant in all respects). Typically, in such cases, no financial benefit at all would have been conferred upon the physician(s). (We note that the OIG subsequently imposed a $50,000 minimum settlement amount in its March 24, 2009 Open Letter.)

While it is understandable that CMS might desire additional time and practical experience in operating under the SRDP before announcing penalty guidelines, the complete uncertainty at this time may prove highly discouraging to providers that are wrestling with the issue of a potential self-disclosure. This may prove particularly true in the case of purely technical violations. Although the provider community (most notably, the American Hospital Association, in its July 16 letter to DHHS Secretary Kathleen Sebelius, as discussed in our Legal News Alert of August 25, 2010), had advocated that CMS implement an expedited review process and a stipulated, modest penalty amount for technical violations, CMS's guidance declines to do so. The guidance, in fact, makes no distinction at all between technical violations and more serious violations, such as those involving arrangements inconsistent with fair market value, where physicians may be unjustly enriched.

Another question that remains shrouded in uncertainty is how providers are to determine the date on which an overpayment was "identified" (and, therefore, when the 60-day reporting and refund deadline begins to run). CMS has yet to provide regulatory guidance as to how it will interpret this provision, although the statutory refund obligation became effective at the time of PPACA's enactment. Given the complexity and nuances of the Stark statute and regulations, internal investigations and careful legal assessments of possible violations can consume a substantial period of time. Lawyers have often taken the position that only clear Stark violations must be reported, and arriving at a determination as to whether a clear violation has occurred can require careful deliberations, often involving not only management but a provider's full governing board. CMS's SRDP guidance, expressly referencing the 60-day reporting and refund requirement, states that "it is imperative for disclosing parties to disclose matters in a timely fashion once identified." Arguably, this implies that CMS will reject disclosures that it believes were not made within the 60-day deadline, but this issue also remains open to question.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions